Table 5.
Changes in the proportion of PBL subsets in patients before and after treatment (%).
| NAs group | NAs + FZHY group | |||||||
|---|---|---|---|---|---|---|---|---|
| n | Pre | Post | Post-Pre | n | Pre | Post | Post-Pre | |
| CD4+T cells | 35 | 35.72 ± 10.10 | 35.40 ± 10.68 | −0.32 ± 11.98 | 35 | 32.16 ± 8.19 | 37.39 ± 9.17∗ | 5.22 ± 9.96△ |
| CD8+T cells | 35 | 31.55 ± 9.38 | 32.72 ± 10.52 | 1.17 ± 12.71 | 35 | 30.18 ± 5.58 | 28.89 ± 9.55 | −1.28 ± 10.97 |
| NK cells | 35 | 16.43 ± 7.13 | 16.70 ± 9.25 | 0.31 ± 5.99 | 35 | 17.64 ± 7.15 | 21.14 ± 8.97△△ | 3.19 ± 5.12 |
∗ P < 0.05 versus Pre CD4+T cells of NAs + FZHY group; ΔP < 0.05 versus Post-Pre CD4+T cells of NAs group; ΔΔP < 0.05 versus Pre NK cells of NAs + FZHY group. PBL, peripheral blood lymphocyte.